NCT04430699View on ClinicalTrials.gov

Cisplatin+Pembrolizumab+RT in Vulvar Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

December 30, 2025

Study Completion Date

January 30, 2028

Conditions
Vulvar CancerVulvar Squamous Cell Carcinoma
Interventions
DRUG

Cisplatin

Participants will be given Cisplatin by intravenous infusion at a predetermined dose 1x weekly up to 8 weeks.

DRUG

Pembrolizumab

Participants will be given Pembrolizumab by intravenous infusion at a predetermined dose 1x every 3 weeks up to 36 weeks.

RADIATION

Radiation Therapy

Standard of care radiation therapy 1x daily up to 8 weeks.

Trial Locations (2)

02114

Massachusetts General Hospital Cancer Center, Boston

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Massachusetts General Hospital

OTHER